The Fibroid Phenotype of Biological Naïve Patients with Rheumatoid Arthritis Are Less Likely to Respond to Anti-IL-6R Treatment

Overview

Journal Sci Rep

Specialty Science

Date 2024 May 10

PMID 38730088

Authors

Sofie Falkenlove Madsen

Dovile Sinkeviciute

Christian S Thudium

Morten A Karsdal

Anne-Christine Bay-Jensen

Affiliations

Soon will be listed here.

Abstract

Type III collagen gene expression is upregulated in the synovium of patients with rheumatoid arthritis (RA) presenting the fibroid phenotype. The soluble type III collagen formation biomarker, PRO-C3, is known to measure fibrogenesis in fibrotic diseases. In this exploratory study, we aimed to investigate the association between fibrogenesis (PRO-C3) and the disease- and treatment response in patients with RA. We measured PRO-C3 in subsets of two clinical trials assessing the effect of the anti-interleukin-6 (IL-6) receptor treatment tocilizumab (TCZ) as monotherapy or polytherapy with methotrexate. PRO-C3 levels had weak or very weak correlations with the clinical parameters (Spearman's). However, when the patients were divided into Disease Activity Score-28 groups characterized by the erythrocyte sedimentation rate (DAS28-ESR), there was a statistical difference between the PRO-C3 levels of the different groups (p < 0.05). To determine the response in relation to PRO-C3, a cut-off based on PRO-C3 levels and patients in remission (DAS28-ESR ≤ 2.6) was identified. This showed that a reduction in PRO-C3 after treatment initiation was associated with decreased DAS28-ESR and a higher response rate in patients with low PRO-C3 levels than in those with high PRO-C3 levels. This indicates that a fibrotic component affects the responsiveness of patients.

References

Doyle T, Patel A, Hatabu H, Nishino M, Wu G, Osorio J . Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med. 2015; 191(12):1403-12. PMC: 4476561. DOI: 10.1164/rccm.201411-1950OC. View

Drobinski P, Nissen N, Sinkeviciute D, Willumsen N, Karsdal M, Bay-Jensen A . In Contrast to Anti-CCP, MMP-Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and a Treatment Response Biomarker. Int J Mol Sci. 2023; 24(1). PMC: 9820189. DOI: 10.3390/ijms24010321. View

Bay-Jensen A, Platt A, Siebuhr A, Christiansen C, Byrjalsen I, Karsdal M . Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Res Ther. 2016; 18:13. PMC: 4719735. DOI: 10.1186/s13075-015-0913-x. View

Drobinski P, Bay-Jensen A, Karsdal M, Sardar S, Siebuhr A . Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study. Arthritis Res Ther. 2021; 23(1):13. PMC: 7789531. DOI: 10.1186/s13075-020-02378-7. View

Behrens F, Koehm M, Schwaneck E, Schmalzing M, Gnann H, Greger G . Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis. BMC Rheumatol. 2019; 3:51. PMC: 6902502. DOI: 10.1186/s41927-019-0095-2. View

Organ L, Duggan A, Oballa E, Taggart S, Simpson J, Kangombe A . Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2019; 20(1):148. PMC: 6624898. DOI: 10.1186/s12931-019-1118-7. View

Kubo S, Siebuhr A, Bay-Jensen A, Juhl P, Karsdal M, Satoh Y . Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. Int J Rheum Dis. 2020; 23(4):532-539. DOI: 10.1111/1756-185X.13804. View

Juhl P, Iversen L, Karlsmark T, Karsdal M, Bay-Jensen A, Mogensen M . Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study. Biomarkers. 2019; 24(4):373-378. DOI: 10.1080/1354750X.2019.1587509. View

Kronzer V, Hayashi K, Yoshida K, Davis 3rd J, McDermott G, Huang W . Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study. Lancet Rheumatol. 2023; 5(2):e77-e87. PMC: 9979957. DOI: 10.1016/s2665-9913(22)00380-0. View

10.

Todd K, Funk K, FUNK J, Bonacci R . Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996; 27(4):485-9. DOI: 10.1016/s0196-0644(96)70238-x. View

11.

Sergeant J, Hyrich K, Anderson J, Kopec-Harding K, Hope H, Symmons D . Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018; 20(1):147. PMC: 6044018. DOI: 10.1186/s13075-018-1645-5. View

12.

Kelly A . Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain?. Acad Emerg Med. 1998; 5(11):1086-90. DOI: 10.1111/j.1553-2712.1998.tb02667.x. View

13.

Erhardtsen E, Rasmussen D, Frederiksen P, Leeming D, Shevell D, Gluud L . Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. JHEP Rep. 2021; 3(4):100317. PMC: 8385245. DOI: 10.1016/j.jhepr.2021.100317. View

14.

Dobrota R, Jordan S, Juhl P, Maurer B, Wildi L, Bay-Jensen A . Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatol. 2024; 3(3):e175-e184. DOI: 10.1016/S2665-9913(20)30385-4. View

15.

Humby F, Lewis M, Ramamoorthi N, Hackney J, Barnes M, Bombardieri M . Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis. 2019; 78(6):761-772. PMC: 6579551. DOI: 10.1136/annrheumdis-2018-214539. View

16.

Juhl P, Thudium C, Gudmann N, Karsdal M, Bay-Jensen A, Siebuhr A . IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab.... Clin Exp Rheumatol. 2018; 36(4):568-574. View

17.

Emery P, Keystone E, Tony H, Cantagrel A, Vollenhoven R, Sanchez A . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008; 67(11):1516-23. PMC: 3811149. DOI: 10.1136/ard.2008.092932. View

18.

Scott D, Wolfe F, Huizinga T . Rheumatoid arthritis. Lancet. 2010; 376(9746):1094-108. DOI: 10.1016/S0140-6736(10)60826-4. View

19.

Lewis M, Barnes M, Blighe K, Goldmann K, Rana S, Hackney J . Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep. 2019; 28(9):2455-2470.e5. PMC: 6718830. DOI: 10.1016/j.celrep.2019.07.091. View

20.

Nielsen M, Dolman G, Harris R, Frederiksen P, Chalmers J, Grove J . PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Rep. 2023; 5(6):100743. PMC: 10240276. DOI: 10.1016/j.jhepr.2023.100743. View